Method for detecting pazopanib drug concentration in human plasma by LC-MS/MS (liquid chromatography-mass spectrometry/mass spectrometry)

Abstract

The invention discloses a method for detecting the drug concentration of pazopanib in human plasma through LC-MS / MS combination, and belongs to the technical field of drug concentration analysis. Themethod comprises the following steps: respectively mixing a series of pazopanib working solutions with human blank plasma, performing pre-treating, injecting the mixture into LC-MS / MS for analysis, adding an internal standard working solution mainly prepared from pazopanib-d6 into human plasma to be detected, performing pre-treating, injecting the mixture into LC-MS / MS for analysis, drawing a standard curve by taking the chromatographic peak area ratio of pazopanib to internal standard pazopanib-d6 as an ordinate and the concentration of pazopanib in human blank plasma as an abscissa, and calculating the concentration of pazopanib in the human plasma sample to be detected according to the standard curve, wherein a protein precipitation method is adopted to pretreat a human plasma sample, an electrospray ion source is adopted as an ionization technology, and the detection method is simple and convenient to operate, high in sensitivity, good in reproducibility, high in selectivity, shortin analysis time and suitable for large-batch detection of clinical samples.

Description

technical field [0001] The invention relates to a method for detecting drug concentration, and belongs to the technical field of drug concentration analysis, in particular to a method for detecting the drug concentration of pazopanib in human plasma by combining LC-MS / MS. Background technique [0002] Renal cell carcinoma (RCC) is one of the most common malignant tumors of the urinary system, accounting for more than 80% of renal malignant tumors. The onset of RCC is hidden, and more than 30% of patients have been diagnosed with metastasis, and RCC is not sensitive enough to radiotherapy and chemotherapy. In the past 10 years, with the development of targeted drugs, the treatment of metastatic RCC has entered the era of targeted therapy. [0003] Pazopanib hydrochloride was developed by GlaxoSmithKline and was approved by the U.S. Food and Drug Administration (FDA) in October 2009 for listing in the U.S. under the trade name Votrient for the treatment of advanced renal cell...

AI Technical Summary

Problems solved by technology

[0008] However, the above detection involves mouse plasma, which is different from human plasma. Therefore, it is urgent to develop a rapid, sensitive and accurate detection method for pazopanib in human plasma.

Images